NASDAQ: GPCR - Structure Therapeutics Inc.

Rentabilität für sechs Monate: -47.38%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Structure Therapeutics Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Structure Therapeutics Inc.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

weitere details
The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2023-02-03
ISIN US86366E1064
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://structuretx.com
Цена ао 20.4
Preisänderung pro Tag: +3.19% (20.4)
Preisänderung pro Woche: -6.94% (22.62)
Preisänderung pro Monat: -13.48% (24.33)
Preisänderung über 3 Monate: -32.64% (31.25)
Preisänderung über sechs Monate: -47.38% (40)
Preisänderung pro Jahr: -40.54% (35.4)
Preisänderung über 3 Jahre: 0% (21.05)
Preisänderung über 5 Jahre: 0% (21.05)
Preisänderung über 10 Jahre: 0% (21.05)
Preisänderung seit Jahresbeginn: -24.55% (27.9)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 2.88 6
P/E 0 0
EV/EBITDA -11.6 0
Gesamt: 2.75

Effizienz

Name Bedeutung Grad
ROA, % -18.58 0
ROE, % -19.77 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.0536 10
Gesamt: 9.6

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 0 0
Rentabilität Ebitda, % 640268.75 10
Rentabilität EPS, % 31968.75 10
Gesamt: 8
Weitere Details

Institutionen Volumen Aktie, %
Wellington Management Group, LLP 4372326 9.38
FMR, LLC 4034584 8.66
Driehaus Capital Management, LLC 2599079 5.58
Avoro Capital Advisors LLC 2333333 5.01
Federated Hermes, Inc. 2267206 4.87
Tcg Crossover Management, Llc 2109584 4.53
Adage Capital Partners GP L.L.C. 1756918 3.77
Price (T.Rowe) Associates Inc 1679436 3.6
Janus Henderson Group PLC 1544416 3.31
T. Rowe Price Investment Management, Inc. 1312195 2.82

ETFAktie, %Rentabilität für das Jahr, %Dividenden, %
Future Tech ETF 0.24233 426.34 0.8416
Principal Healthcare Innovators ETF 0.24233 618.5 0.8416
0.24522.420.84



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Raymond C. Stevens Ph.D. CEO & Director 890.38k 1964 (61 Jahr)
Dr. Yingli Ma Ph.D. Chief Technology Officer 497.58k 1974 (51 Jahr)
Mr. Jun S. Yoon Co- Founder, CFO & Secretary 627.64k 1978 (47 Jahre)
Dr. Xichen Lin Ph.D. Chief Scientific Officer N/A 1974 (51 Jahr)
Mr. Tony Peng Senior Vice President of Legal N/A
Mr. Bob Gatmaitan Senior Vice President of People N/A
Dr. Hui Lei Ph.D. Senior Vice President of Chemistry N/A
Dr. Fang Zhang Ph.D. Executive VP & Head of Biology N/A
Ms. Lani Ibarra Senior Vice President of Clinical Development Operations N/A
Dr. Xinglong Jiang Ph.D. Senior Vice President of Preclinical Development

Adresse: United States, South San Francisco. CA, 611 Gateway Boulevard - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://structuretx.com